Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:ALXO NASDAQ:FGEN NASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$55.22+0.1%$42.58$25.17▼$55.67$9.19B0.342.58 million shs1.72 million shsALXOALX Oncology$2.36+7.8%$1.84$0.44▼$2.66$294.69M0.421.93 million shs1.82 million shsFGENFibroGen$9.77+8.3%$9.21$4.85▼$12.60$39.57M0.7740,794 shs31,125 shsPCRXPacira BioSciences$25.82+0.9%$23.68$18.80▼$27.64$1.01B0.27442,602 shs457,756 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+0.15%+5.38%+29.02%+58.82%+88.92%ALXOALX Oncology+7.76%+14.01%+53.25%+24.54%+431.53%FGENFibroGen0.00%0.00%0.00%0.00%+81.94%PCRXPacira BioSciences+0.90%+1.77%+13.49%+11.05%+11.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$55.22+0.1%$42.58$25.17▼$55.67$9.19B0.342.58 million shs1.72 million shsALXOALX Oncology$2.36+7.8%$1.84$0.44▼$2.66$294.69M0.421.93 million shs1.82 million shsFGENFibroGen$9.77+8.3%$9.21$4.85▼$12.60$39.57M0.7740,794 shs31,125 shsPCRXPacira BioSciences$25.82+0.9%$23.68$18.80▼$27.64$1.01B0.27442,602 shs457,756 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+0.15%+5.38%+29.02%+58.82%+88.92%ALXOALX Oncology+7.76%+14.01%+53.25%+24.54%+431.53%FGENFibroGen0.00%0.00%0.00%0.00%+81.94%PCRXPacira BioSciences+0.90%+1.77%+13.49%+11.05%+11.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.72Moderate Buy$49.63-10.13% DownsideALXOALX Oncology 2.67Moderate Buy$4.6094.92% UpsideFGENFibroGen 2.00Hold$43.00340.12% UpsidePCRXPacira BioSciences 2.29Hold$29.4013.87% UpsideCurrent Analyst Ratings BreakdownLatest PCRX, ALKS, ALXO, and FGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2026ALKSAlkermes MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$53.00 ➝ $65.007/1/2026PCRXPacira BioSciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.006/29/2026ALKSAlkermes Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$44.00 ➝ $65.006/29/2026ALKSAlkermes Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform6/26/2026ALXOALX Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026ALKSAlkermes Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$54.00 ➝ $61.006/22/2026ALKSAlkermes TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $50.006/18/2026ALKSAlkermes HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral6/18/2026ALKSAlkermes Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $54.006/9/2026ALKSAlkermes Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $56.005/20/2026PCRXPacira BioSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)(Data available from 7/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.48B6.24$1.68 per share32.93$11.02 per share5.01ALXOALX OncologyN/AN/AN/AN/A$0.48 per shareN/AFGENFibroGen$29.62M1.34N/AN/A($50.89) per share-0.19PCRXPacira BioSciences$726.41M1.40$3.89 per share6.63$16.11 per share1.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$241.66M$0.9061.36190.41N/A9.78%9.26%5.66%7/28/2026 (Estimated)ALXOALX Oncology-$101.69M-$1.49N/AN/AN/AN/A-124.06%-85.57%8/11/2026 (Estimated)FGENFibroGen-$47.58M$53.480.18N/AN/A2,598.55%N/A-26.27%N/APCRXPacira BioSciences$7.03M$0.12215.189.53N/A0.70%10.24%5.47%8/4/2026 (Estimated)Latest PCRX, ALKS, ALXO, and FGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026PCRXPacira BioSciences$0.64N/AN/AN/A$191.06 millionN/A7/28/2026Q2 2026ALKSAlkermes-$0.04N/AN/AN/A$459.47 millionN/A5/8/2026Q1 2026ALXOALX Oncology-$0.15-$0.17-$0.02-$0.17N/AN/A4/30/2026Q1 2026PCRXPacira BioSciences$0.61$0.60-$0.01$0.07$171.80 million$177.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AALXOALX OncologyN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermes0.852.271.70ALXOALX Oncology0.027.217.21FGENFibroGenN/A3.713.60PCRXPacira BioSciences0.564.733.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%ALXOALX Oncology97.97%FGENFibroGen72.71%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.59%ALXOALX Oncology21.00%FGENFibroGen3.07%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,050166.68 million159.03 millionOptionableALXOALX Oncology40134.56 million106.31 millionOptionableFGENFibroGen5704.05 million3.92 millionOptionablePCRXPacira BioSciences72039.35 million36.83 millionOptionablePCRX, ALKS, ALXO, and FGEN HeadlinesRecent News About These CompaniesPCRX's Exparel wins separate reimbursement from UnitedHealthcareJuly 2, 2026 | msn.comPacira to Divest iovera Business to Zimmer Biomet in Up To $140M DealJuly 1, 2026 | zacks.comHC Wainwright Reaffirms "Buy" Rating for Pacira BioSciences (NASDAQ:PCRX)July 1, 2026 | marketbeat.comPacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®July 1, 2026 | globenewswire.comPacira BioSciences to Divest iovera° to Zimmer Biomet for Up to $140 MillionJune 30, 2026 | quiverquant.comQPacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer BiometJune 30, 2026 | globenewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of "Hold" by BrokeragesJune 28, 2026 | americanbankingnews.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from AnalystsJune 28, 2026 | marketbeat.comRice Hall James & Associates LLC Decreases Stock Holdings in Pacira BioSciences, Inc. $PCRXJune 16, 2026 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) SVP Lauren Riker Sells 6,115 SharesJune 13, 2026 | insidertrades.comGagnon Securities LLC Acquires 51,494 Shares of Pacira BioSciences, Inc. $PCRXJune 13, 2026 | marketbeat.comGagnon Advisors LLC Has $6.75 Million Position in Pacira BioSciences, Inc. $PCRXJune 13, 2026 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Stock Crosses Below 50 Day Moving Average - Should You Sell?June 12, 2026 | marketbeat.comPacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual MeetingJune 9, 2026 | prnewswire.comPacira BioSciences, Inc. (PCRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comPacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual MeetingJune 4, 2026 | prnewswire.comPacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director NomineesJune 1, 2026 | prnewswire.comPharmaCorp Rx Inc. Announces First Quarter 2026 Financial ResultsJune 1, 2026 | globenewswire.comConsidering Pacira Biosciences Inc (PCRX) Stock After Q1 Report? Check the DetailsMay 29, 2026 | uk.finance.yahoo.comPacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified NomineesMay 29, 2026 | finance.yahoo.comLeading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote âFORâ All of Paciraâs Director Nominees May 28, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 2026SMRs Spark a Chain Reaction for Nano NuclearBy Jeffrey Neal Johnson | July 2, 2026PCRX, ALKS, ALXO, and FGEN Company DescriptionsAlkermes NASDAQ:ALKS$55.22 +0.08 (+0.15%) Closing price 07/7/2026 04:00 PM EasternExtended Trading$55.22 +0.01 (+0.01%) As of 07/7/2026 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.ALX Oncology NASDAQ:ALXO$2.36 +0.17 (+7.76%) Closing price 07/7/2026 04:00 PM EasternExtended Trading$2.30 -0.06 (-2.75%) As of 07/7/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.FibroGen NASDAQ:FGENFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Pacira BioSciences NASDAQ:PCRX$25.82 +0.23 (+0.90%) Closing price 07/7/2026 04:00 PM EasternExtended Trading$25.83 +0.01 (+0.04%) As of 07/7/2026 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Apple and Broadcom Forge a Decade-Long Silicon Fortress SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity Palantir's CEO Just Called Out OpenAI and Anthropic Silicon Starvation: Amazon Feasts on Legacy GPUs GE Vernova’s Power Surge Turns the Grid Into an AI Trade 3 Quiet AI Revenue Accelerators With Sales Growth Outpacing Peers Abivax: Wall Street Catches Up to the Data Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
